



**Brand Favored Product List
Colorado Medical Assistance Program
Health First Colorado Pharmacy Benefit
For Physicians and Pharmacists**

Multi-source drug products with favored coverage for a brand name equivalent formulation are listed in this document. Drug products listed in this document include products not managed on the Preferred Drug List (PDL), as well as preferred and non-preferred products included on the PDL (accessible at <https://www.colorado.gov/hcpf/pharmacy-resources#PDL>).

Determination for products included on the Brand Favored Product List is based on evaluation of cases where the cost of a generic product formulation exceeds the cost of the brand name equivalent.

Billing Information:

Pharmacy claims for brand medications/dosage forms included on the Brand Favored Product List will allow for payment with submission of DAW codes 1 or 9 on the incoming claim. PDL products included in the list may also be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

Prior Authorization for Use of a Generic Equivalent(s) Included on the Brand Favored Product List:

Generic equivalent products for the brand medications/dosage forms included on the Brand Favored Product List will require prior authorization and may receive approval based on prescriber verification that there is clinical necessity of use of the generic equivalent product formulation.

Prior authorization requests may be called or faxed to the Magellan pharmacy helpdesk at:

Phone: 1-800-424-5725
Fax: 1-888-424-5881.

BRAND FAVORED PRODUCT LIST

On January 27, 2022 the following products have been removed from the Brand Favored Product List:

- Colcrys (colchicine) tablet
- Kitabis (tobramycin) pak
- Tecfidera (dimethyl fumarate) tablet, pak

NON-PDL BRAND FAVORED PRODUCTS	
<u>Drug Product</u>	<u>Effective Date</u>
Afinitor (everolimus) disperz tablet	1/1/2022
Amicar® (aminocaproic acid) solution	10/15/2020
Buphenyl® (sodium phenylbutyrate) tablet	10/15/2020
Ciprodex® (ciprofloxacin/dexamethasone) suspension	10/15/2020
Noxafil® (posaconazole) tablet	1/20/2020
Rapamune® (sirolimus) solution	5/28/2019
Rapamune® (sirolimus) tablet	10/15/2020
Zavesca® (miglustat) capsule	8/1/2019

PDL PREFERRED BRAND FAVORED PRODUCTS*	
Lidoderm (lidocaine) patch	1/1/2022
Epipen JR 0.15 mg/0.15 ml, (epinephrine) auto-injector	1/1/2022
Epipen 0.3 mg/0.3 ml (epinephrine) auto-injector	1/1/2022
Diclegis DR tablet (doxylamine/pyridoxine)	1/1/2022
Revatio (sildenafil) oral suspension	1/1/2022
Afinitor (everolimus) tablet	11/11/2021
Vivelle-Dot (estradiol) patch	10/1/2021
Climara (estradiol) patch	10/1/2021
Minivelle (estradiol) patch	10/1/2021
Nuvaring® (etonogestrel/ethinyl estradiol) vaginal ring	10/1/2021
Delestrogen (estradiol valerate) vial	10/1/2021
Bystolic (nebivolol) tablet	9/17/2021
Finacea (azelaic acid) gel	7/1/2021
Metrogel (metronidazole)	7/1/2021
Renvela (sevelamer carbonate) tablet	7/1/2021
Renvela (sevelamer carbonate) powder pack	7/1/2021
Androgel (testosterone) gel 1.62% pump	7/1/2021
Androgel (testosterone) gel packet	7/1/2021
Aczone (dapsone) gel	7/1/2021
Retin-A (tretinoin) cream, gel	7/1/2021
Renagel (sevelamer HCl) tablet	6/15/2021
Elidel (pimecrolimus) cream	6/15/2021
Butrans (buprenorphine) transdermal patch	7/1/2019
Zovirax (acyclovir) cream	2/20/2019
Tracleer 62.5mg, 125mg (bosentan) tablet	5/16/2019
Felbatol (felbamate) tablet, suspension	10/1/2018
Adderall XR (mixed amphetamine salts ER)	9/1/2020
Concerta (methylphenidate ER) tablet	10/1/2017
Imitrex (sumatriptan) nasal spray	1/1/2021
Differin (adapalene) gel pump	7/1/2018
Dovonex (calcipotriene) cream	1/1/2020
Taclonex Scalp (calcipotriene/betamethasone) suspension	1/1/2019
Taclonex Ointment (calcipotriene/betamethasone)	1/1/2019
Protopic Ointment (tacrolimus)	7/1/2020
Derma-Smoothe-FS (fluocinolone acetonide) oil	4/1/2019
Nexium (esomeprazole) packets	2/25/2017
Apriso ER (mesalamine ER) capsule	11/26/2019

*Products included in this section may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

PDL PREFERRED BRAND FAVORED PRODUCTS*	
Lialda (mesalamine DR) tablet	1/1/2019
Copaxone (glatiramer) 20 mg injection	4/1/2017
Gilenya (fingolimod) 0.5 mg tablet (30-ct bottle)	12/13/2019
Lotemax (loteprednol) 0.5% drops	7/2/2019
Travatan Z (travoprost)	1/1/2020
Alphagan P 0.15% (brimonidine)	4/1/2020
Proair (albuterol) HFA	2/18/2019
Ventolin (albuterol) HFA inhaler	4/10/2020
Advair Diskus (fluticasone/salmeterol)	11/1/2019
Symbicort (budesonide/formoterol) inhaler	1/16/2018

*Products included in this section may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

PDL NON-PREFERRED BRAND FAVORED PRODUCTS*	
<u>Drug Product</u>	<u>Effective Date</u>
Banzel (rufinamide) tablet	11/11/2021
Duexis (ibuprofen-famotidine)	8/13/2021

*Products included in this section may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

NON-PDL BRAND FAVORED PRODUCTS	
<u>Drug Product</u>	<u>Effective Date</u>
Afinitor (everolimus) disperz tablet	1/1/2022
Amicar® (aminocaproic acid) solution	10/15/2020
Buphenyl® (sodium phenylbutyrate) tablet	10/15/2020
Ciprodex® (ciprofloxacin/dexamethasone) suspension	10/15/2020
Noxafil® (posaconazole) tablet	1/20/2020
Rapamune® (sirolimus) solution	5/28/2019
Rapamune® (sirolimus) tablet	10/15/2020
Zavesca® (miglustat) capsule	8/1/2019

PDL NON-PREFERRED BRAND FAVORED PRODUCTS*	
<u>Drug Product</u>	<u>Effective Date</u>
Banzel (rufinamide) tablet	11/11/2021
Duexis (ibuprofen-famotidine)	8/13/2021
Banzel (rufinamide) suspension	4/22/2021
Copaxone® (glatiramer) 40mg solution	10/15/2020
Dymista® (azelastine/fluticasone) spray	4/1/2019
Flector® (diclofenac) topical system	5/14/2020
Lotronex® (alosetron) tablet	4/1/2018

*Products included in this section may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.

PDL NON-PREFERRED BRAND FAVORED PRODUCTS*	
Protonix (pantoprazole) Suspension	4/22/2021
Sabril® (vigabatrin) tablet/solution	7/16/2019
Vimovo® (naproxen/esomeprazole) DR tablet	2/26/2020

**Products included in this section may be subject to prior authorization criteria and coverage limitations listed for the product on the PDL.*